Ohr Pharmaceutical Inc (OHRP): Samuel Backenroth , Chief Financial Officer of Ohr Pharmaceutical Inc purchased 2,468 shares on Jun 20, 2016. The Insider buying transaction was reported by the company on Jun 21, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.84 per share for a total value of $6,997.44 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 21, 2016, Samuel Backenroth (Chief Financial Officer) purchased 2,468 shares at $2.84 per share price.On May 26, 2016, Jason Scott Slakter (CEO) purchased 3,682 shares at $3.12 per share price.Also, On Feb 10, 2015, Irach B. Taraporewala (CEO) purchased 3,705 shares at $6.75 per share price.On Feb 10, 2015, June Sherie Almenoff (director) purchased 6,000 shares at $6.75 per share price.
OHR Pharmaceutical Inc: On Monday, Jun 20, 2016 heightened volatility was witnessed in OHR Pharmaceutical Inc which led to swings in the share price. The shares opened for trading at $2.69 and hit $2.92 on the upside , eventually ending the session at $2.76, with a gain of 2.99% or 0.08 points. The heightened volatility saw the trading volume jump to 1,86,562 shares. The 52-week high of the share price is $6.56 and the company has a market cap of $87 M . The 52-week low of the share price is at $2.02.
Company has been under the radar of several Street Analysts.OHR Pharmaceutical Inc is Resumed by ROTH Capital to Buy and the brokerage firm has set the Price Target at $13. The Rating was issued on Jun 16, 2016.
Ohr Pharmaceutical Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of various programs and indications at various stages of development. The Company’s clinical program OHR-102 eye drops is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops which is given in combination with Lucentis injections for the treatment of retinal diseases including wet-age-related macular degeneration (AMD) retinal vein occlusion and proliferative diabetic retinopathy. The Company’s product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action.